Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial
University of Cologne · Düsseldorf University Hospital · +54 more institutions
Abstract
BackgroundIntensified systemic chemotherapy has the highest primary cure rate for advanced-stage, classical Hodgkin lymphoma but this comes with a cost of severe and potentially life long, persisting toxicities. With the new regimen of brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD), we aimed to improve the risk-to-benefit ratio of treatment of advanced-stage, classical Hodgkin lymphoma guided by PET after two cycles.MethodsThis randomised, multicentre, parallel, open-label, phase 3 trial was done in 233 trial sites across nine countries. Eligible patients were adults (aged ≤60 years) with newly diagnosed, advanced-stage, classical Hodgkin lymphoma (ie,…
Citation impact
- FWCI
- 40.23
- Percentile
- 100%
- References
- 34
Authors
50- PBPeter BorchmannCorresponding
University of Cologne, Düsseldorf University Hospital, German Inflammatory Bowel Diseases Study Group, University Hospital Cologne, Heinrich Heine University Düsseldorf
- JFJustin Ferdinandus
University of Cologne, Düsseldorf University Hospital, German Inflammatory Bowel Diseases Study Group, University Hospital Cologne, Heinrich Heine University Düsseldorf
- GSGundolf Schneider
University of Cologne, Düsseldorf University Hospital, German Inflammatory Bowel Diseases Study Group, University Hospital Cologne, Heinrich Heine University Düsseldorf
- AAAlden A. Moccia
Institute of Oncology Research, Swiss Group For Clinical Cancer Research
- RGRichard Greil
Paracelsus Medical University, Unfallkrankenhaus Salzburg, Salzburger Landeskliniken
Topics & keywords
- Tolerability
- Medicine
- Open label
- Stage (stratigraphy)
- Lymphoma
- Oncology
- Randomized controlled trial
- Internal medicine
- Zero hunger